{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:34:46Z","timestamp":1791178486712,"version":"4.1.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2012,5,18]],"date-time":"2012-05-18T00:00:00Z","timestamp":1337299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2012,5,18]],"date-time":"2012-05-18T00:00:00Z","timestamp":1337299200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1038\/leu.2012.134","type":"journal-article","created":{"date-parts":[[2012,5,18]],"date-time":"2012-05-18T06:37:33Z","timestamp":1337323053000},"page":"2197-2203","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":357,"title":["Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up"],"prefix":"10.1038","volume":"26","author":[{"given":"R A","family":"Larson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Hochhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T P","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R E","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Etienne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D-W","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I W","family":"Flinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Kurokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Moiraghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R E","family":"Blakesley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N J","family":"Gallagher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Saglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H M","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,5,18]]},"reference":[{"key":"BFleu2012134_CR1","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","volume":"7","author":"E Weisberg","year":"2005","unstructured":"Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, Ray A et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005; 7: 129\u2013141.","journal-title":"Cancer Cell"},{"key":"BFleu2012134_CR2","unstructured":"Tasigna (package insert). Novartis Pharmaceuticals Corporation: East Hanover, NJ, 2010."},{"key":"BFleu2012134_CR3","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010; 362: 2251\u20132259.","journal-title":"N Engl J Med"},{"key":"BFleu2012134_CR4","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/S1470-2045(11)70201-7","volume":"12","author":"HM Kantarjian","year":"2011","unstructured":"Kantarjian HM, Hochhaus A, Saglio G, De Souza C, Flinn IW, Stenke L et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol 2011; 12: 841\u2013851.","journal-title":"Lancet Oncol"},{"key":"BFleu2012134_CR5","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1038\/leu.2009.38","volume":"23","author":"A Hochhaus","year":"2009","unstructured":"Hochhaus A, O'Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009; 23: 1054\u20131061.","journal-title":"Leukemia"},{"key":"BFleu2012134_CR6","doi-asserted-by":"publisher","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","volume":"27","author":"M Baccarani","year":"2009","unstructured":"Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009; 27: 6041\u20136051.","journal-title":"J Clin Oncol"},{"key":"BFleu2012134_CR7","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1182\/blood-2011-08-369017","volume":"118","author":"R Larson","year":"2011","unstructured":"Larson R, Bunworasate U, Turkina A, Goldberg A, Dorlhiac-Llacer P, Lopez J et al. Nilotinib shows safety and efficacy in older patients (\u2a7e65 years) with newly diagnosed chronic myeloid leukemia in chronic phase comparable with that in younger patients with chronic myeloid leukemia in chronic phase: results from ENESTnd. Blood 2011; 118: 1608\u20131609.","journal-title":"Blood"},{"issue":"10","key":"BFleu2012134_CR8","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1038\/leu.2012.104","volume":"26","author":"N C P Cross","year":"2012","unstructured":"Cross NCP, White H, M\u00fcller MC, Saglio G, Hochhaus A . Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia 2012; e-pub ahead of print 16 April 2012 doi:10.1038\/leu.2012.104.","journal-title":"Leukemia"},{"key":"BFleu2012134_CR9","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"FX Mahon","year":"2010","unstructured":"Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini F et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010; 11: 1029\u20131035.","journal-title":"Lancet Oncol"},{"key":"BFleu2012134_CR10","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1080\/10428190902926973","volume":"50","author":"HG Goh","year":"2009","unstructured":"Goh HG, Kim YJ, Kim DW, Kim HJ, Kim SH, Jang SE et al. Previous best responses can be re-achieved by resumption after imatinib discontinuation in patients with chronic myeloid leukemia: implication for intermittent imatinib therapy. Leuk Lymphoma 2009; 50: 944\u2013951.","journal-title":"Leuk Lymphoma"},{"key":"BFleu2012134_CR11","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1182\/blood.V118.21.3765.3765","volume":"118","author":"E Matsuki","year":"2011","unstructured":"Matsuki E, Ono Y, Sakurai M, Kunimoto H, Ishizawa J, Shimizu T et al. Discontinuation of imatinib in patients with CML and sustained complete molecular response (CMR) for over 2 years in the Japanese population\u2014an interim analysis of KEIO STIM study. Blood 2011; 118: 1608 [abstract 3765].","journal-title":"Blood"},{"key":"BFleu2012134_CR12","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1182\/blood.V118.21.277.277","volume":"118","author":"D Rea","year":"2011","unstructured":"Rea D, Rousselot P, Nicolini FE, Legros L, Tulliez M, Giraudier S et al. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia (CML) patients (pts) with stable undetectable Bcr-Abl transcripts: results from the French CML Group (FILMC). Blood 2011; 118: 277.","journal-title":"Blood"},{"key":"BFleu2012134_CR13","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1038\/leu.2010.185","volume":"10","author":"DM Ross","year":"2010","unstructured":"Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Bartley PA et al. Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia 2010; 10: 1719\u20131724.","journal-title":"Leukemia"}],"updated-by":[{"DOI":"10.1038\/leu.2012.175","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2012,10,10]],"date-time":"2012-10-10T00:00:00Z","timestamp":1349827200000}}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2012134.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2012134","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2012134.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T15:16:11Z","timestamp":1648739771000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2012134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,18]]},"references-count":13,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["BFleu2012134"],"URL":"https:\/\/doi.org\/10.1038\/leu.2012.134","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,18]]},"assertion":[{"value":"1 May 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2012","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2012","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2012","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article has been corrected since Advance Online Publication and a corrigendum is also printed in this issue","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"RAL was a consultant for Novartis, BMS, Pfizer and Ariad, received research funding from Novartis, BMS and Ariad, and received honoraria from Novartis. AH received research funding and honoraria from BMS, Novartis, Pfizer, MSD and Ariad. TPH was a consultant for and received honoraria from Novartis, BMS and Ariad and research funding from Novartis, BMS and CSL. REC received research funding from Novartis and BMS, honoraria from Novartis, BMS and Pfizer, and was on the speakers' bureau for Novartis. GE has no relationships to disclose. D-WK was an advisor for and received research funding from Novartis, BMS and Pfizer, received honoraria from Novartis and BMS, was a consultant for Novartis and BMS, and was on the speaker's bureau for Novartis. IWF received research funding from Novartis. MK was on the speakers' bureau, an advisor, and received research funding from Novartis. BM was on the speakers' bureau for BMS and Novartis. RY and NJG are Novartis employees and stock holders. REB is a Novartis employee. GS is a consultant for Novartis, BMS and Pfizer and on the speakers' bureau for Novartis and BMS. HMK received research funding from Novartis, BMS and Pfizer and is a consultant for Novartis.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}